Identification of Stage I Non-small Cell Lung Cancer Patients at High Risk for Local Recurrence Following Sublobar Resection-Reference-Cited by-同舟云学术

Identification of Stage I Non-small Cell Lung Cancer Patients at High Risk for Local Recurrence Following Sublobar Resection

Published:2013-05 Issue:5 Volume:143 Page:1365-1377
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Varlotto John M.,Medford-Davis Laura N.,Recht Abram,Flickinger John,Yao Nengliang,Hess Clayton,Reed Michael F.,Toth Jennifer,Zander Dani S.,DeCamp Malcolm M.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference33 articles.

1. Lobectomy versus limited resection in T1 N0 lung cancer;Lederle;Ann Thorac Surg,1996

2. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer;Varlotto;Cancer,2009

3. Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer;Varlotto;Int J Radiat Oncol Biol Phys,2011

4. Non-parametric estimation from incomplete observation;Kaplan;J Amer Statist Assoc,1958

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer;Nature Communications;2023-11-18

2. A multi-kernel and multi-scale learning based deep ensemble model for predicting recurrence of non-small cell lung cancer;PeerJ Computer Science;2023-05-02

3. Clinical Outcomes and Prognosis of Patients With Interstitial Lung Disease Undergoing Lung Cancer Surgery: A Propensity Score Matching Study;Clinical Lung Cancer;2023-01

4. Pathologic node-negative lung cancer: Adequacy of lymph node yield and a tool to assess the risk of occult nodal disease;Lung Cancer;2022-12

5. ASO Author Reflections: The Clinical Use of Radiomics with Artificial Intelligence in Patients with Early-Stage Lung Cancer;Annals of Surgical Oncology;2022-09-13